Medicare Response To ESA "Overuse" In CKD Will Await Impact Of Bundled Payments, CMS Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Final CMS decision confirms proposal to withhold a national Medicare coverage policy for erythropoiesis stimulating agents in chronic kidney disease.